At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Thomas Powles. MBBS, MRCP, MD, of Barts Cancer Institute, Queen Mary University of London, London, UK, discusses the results of a phase 2/3 trial, which evaluated if maintenance therapy with lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, after first-line chemotherapy is associated with clinical benefit in patients with HER1/2-positive metastatic transitional cell carcinoma.
Maintenance lapatinib after first-line chemotherapy in HER1/2-positive metastatic bladder cancer
23rd July 2015
Join our mailing list
To receive the EMJ updates straight to your inbox free of charge, please click the button below.Join Now